Beranda › Kanker Prostat › West Virginia
Uji klinis Kanker Prostat di West Virginia
6 studi untuk Kanker Prostat mencari peserta di lokasi di West Virginia.
Kota di West Virginia
Teks studi resmi (Bahasa Inggris)
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- Vandalia Health/CAMC Institute for Academic Medicine, Charleston
Menerima pesertaFase 3
Usia 18 ke atas · Pria · Diperbarui 2 Okt 2026 · NCT06931340Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Edwards Comprehensive Cancer Center, Huntington
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- Edwards Comprehensive Cancer Center, Huntington
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06632977Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- Edwards Comprehensive Cancer Center, Huntington
- West Virginia University Healthcare, Morgantown
- Camden Clark Medical Center, Parkersburg
- dan 1 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Pria · Diperbarui 10 Sep 2026 · NCT05946213SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Morgantown
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- West Virginia University Healthcare, Morgantown
Menerima pesertaFase 3
Usia 18 ke atas · Pria · Diperbarui 11 Sep 2025 · NCT03678025Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.